This relationship has not yet been examined with regards to the genomic profiling of CTCs, but low phenotypic diversity of prostate cancer CTCs has been shown to correlate with improved OS in patients treated with androgen receptor signaling inhibitors (ARSI), whereas high heterogeneity was associated with increased risk of death on ARSI relative to taxanes. The gene discussed is AR; the disease is prostate cancer.